# Mundipharma wins contract to launch Kolon's Invossa in Japan

Mundipharma won an exclusive technology export contract from Kolon Life Science to launch Invossa, a cell-mediated gene therapy for degenerative arthritis, in Japan. The contract is effective for 15 years after launch, with a total value of $591.6 million.

- Type: Contract
- Announced: 2018-11-19
- Where: Japan
- Value: $591.6M
- Status: announced
- Products: Invossa cell-mediated gene therapy
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Kolon Life Science](https://endata.com/companies/32675.md) (supplier)
- [Mundipharma](https://endata.com/companies/35563.md) (customer)

## Sources

- [ajupress.com](https://www.ajupress.com/view/20181119171815123), 2018-11-19: "Mundipharma has exclusive rights to research, develop, patent and commercialize Invossa in Japan."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.